Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Climb Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Climb Bio's regulatory disclosures and financial reporting.
Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 100,000 shares of common stock in open-market transactions on February 12 and 13, 2026. He sold 90,000 shares at a weighted average price of $5.2332 on February 12 and 10,000 shares at a weighted average price of $5.8141 on February 13.
After these sales, Basil directly beneficially owns 204,657 shares of Climb Bio common stock. The filing states the trades were made under a Rule 10b5-1 trading plan adopted on October 14, 2025, and notes that each reported price reflects a weighted average of multiple individual trades within the disclosed price ranges.
The holder of CLYM common stock has filed a notice of proposed sale of 100,000 shares through Morgan Stanley Smith Barney on or after February 12, 2026 on NASDAQ, with an aggregate market value of $556,000. The filing states that 68,184,435 shares of this class were outstanding at the time of the notice.
The shares to be sold were acquired from the issuer as restricted stock units on January 1, 2025 (50,188 shares) and as founders’ shares on November 15, 2023 (49,812 shares). The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Climb Bio, Inc. reported an equity award to its President and CEO, Brennan Aoife, who also serves as a director. On January 6, 2026, Aoife received a stock option to buy 700,000 shares of Climb Bio common stock at an exercise price of $3.81 per share. The filing shows this option is held directly and represents 700,000 derivative securities beneficially owned after the grant.
The option was granted as a long-term incentive. According to the vesting terms, 25% of the underlying shares vest on the first anniversary of the grant date, and the remaining shares vest in 36 equal monthly installments through January 6, 2030, as long as Aoife continues to serve the company. The option has an expiration date of January 5, 2036, giving a long window in which it can be exercised if vested.
Climb Bio, Inc. (CLYM) reported a stock option grant to Chief Business Officer Megan Wilson Perrin on a Form 4. On January 6, 2026, she received a stock option to buy 300,000 shares of common stock at an exercise price of $3.81 per share, expiring on January 5, 2036.
According to the vesting terms, 25% of the option shares vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments through January 6, 2030, conditioned on her continued service with the company.
Climb Bio, Inc. reported that its Chief Financial Officer, Susan Altschuller, received a new stock option grant. On January 6, 2026, she was awarded a stock option to buy 142,500 shares of Climb Bio common stock at an exercise price of $3.81 per share. Following this grant, she beneficially owned 142,500 derivative securities in the form of this option, held directly.
The option vests over time. According to the disclosure, 25% of the shares vest on the first anniversary of the January 6, 2026 grant date, and the remaining shares vest in 36 equal monthly installments through January 6, 2030, as long as she continues in service. The option expires on January 5, 2036.
Climb Bio, Inc. reported that Senior Vice President, Finance Cindy Driscoll received a grant of stock options. On January 6, 2026, she was awarded a stock option to buy 100,000 shares of common stock at an exercise price of $3.81 per share.
According to the grant terms, 25% of the option shares vest on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments through January 6, 2030, as long as she continues in service. Following this grant, she beneficially owns 100,000 stock options directly.
Climb Bio, Inc. reported that its drug development pipeline has progressed and outlined anticipated milestones for 2026, as described in an accompanying press release. The company highlighted updates for its key candidates, including budoprutug and CLYM116, and plans additional clinical activity during 2026.
Climb Bio also stated that, based on its current operating plan, its cash, cash equivalents and marketable securities are expected to fund operations into 2028, while cautioning that this projection depends on assumptions that may prove incorrect and capital could be used sooner. The company emphasized that many forward-looking statements about timelines, regulatory progress and financial runway are subject to significant risks and uncertainties.
Climb Bio, Inc. (CLYM) reported an insider purchase by investment funds managed by RA Capital. On January 5, 2026, RA Capital Healthcare Fund, L.P. bought 7,111 shares of Climb Bio common stock at a weighted average price of about $3.50 per share. After this transaction, entities advised by RA Capital collectively reported 3,403,429 shares held indirectly through RA Capital Healthcare Fund, L.P., along with additional indirect holdings through Sera Medicines, LLC, RA Capital Nexus Fund, L.P., RA Capital Nexus II Fund, L.P., RA Capital Nexus III Fund, L.P., and a separately managed account. RA Capital Management, L.P., its affiliated entities, and individuals Peter Kolchinsky and Rajeev Shah may be deemed beneficial owners through their roles but disclaim beneficial ownership except to the extent of their pecuniary interest.
Climb Bio director and 10% owner entities affiliated with RA Capital reported a major restructuring of their holdings and additional open-market share purchases. On December 11, 2025, RA Capital Healthcare Fund, L.P. exchanged 20,440,000 shares of Climb Bio common stock for a pre-funded warrant exercisable for up to 20,440,000 shares at an exercise price of $0.0001 per share, for no additional consideration.
The filing also reports open-market purchases of Climb Bio common stock: 213,099 shares on December 11, 2025 at a weighted average price of $2.18 per share and 101,462 shares on December 12, 2025 at a weighted average price of $2.86. The warrant has no expiration date, is exercisable immediately, and includes a 33.0% beneficial ownership cap, limiting how many shares can be exercised based on total outstanding stock. Climb Bio shares are held across multiple RA Capital funds and a separately managed account, with beneficial ownership relationships detailed among the affiliated entities.
Climb Bio (CLYM) reported third-quarter results marked by higher R&D investment and a solid liquidity position. Q3 net loss was $12.9 million, driven by research and development of $9.1 million and general and administrative of $5.8 million. For the nine months, net loss was $42.3 million.
Cash, cash equivalents and marketable securities were $175.8 million as of September 30, 2025, with stockholders’ equity of $177.0 million. Operating cash use was $38.7 million year to date. The company established an at‑the‑market program for up to $22.4 million and did not sell shares during the quarter. Shares outstanding were 68,184,435 as of October 31, 2025.
Pipeline progress included FDA clearance for a Phase 2 pMN study of budoprutug and an open‑label Phase 1b/2a study in ITP, with sites being activated and patients being enrolled and dosed. Climb also recorded a $9.0 million upfront expense earlier in the year for the CLYM116 license and noted milestone frameworks with Acelyrin, CRH and ProBioGen tied to future development and sales events.